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This thesis describes the formulation of short-term and mid-term operational excellence
strategies through the use of value stream mapping. It is shown that many interconnected issues
form a backdrop for seemingly independent "symptomatic issues" or issues that can be seen
readily on the surface because of their significant financial or organizational impacts. These
underlying issues indicate organizational improvement projects are necessary in the short term to
create an environment conducive to sustaining results stemming from projects addressing the
surface issues. One example of a surface issue is that of scheduling where the problem can be
readily seen with blockages, starvation, and long cycle times, but must be solved with
organizational and other fundamental improvements for improvements to be sustainable. Also
presented is a case study showing a root cause and financial analysis relating to the capabilities
of the aseptic filling process. The value stream mapping analysis led to recommendations of
working on fundamental organizational, communication, and cultural issues to create a strong
foundation for improvement projects on more visible projects.
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Thesis Introduction
1.1 Introduction to Value Stream Mapping
This section provides an overview of the methods used to analyze the aseptic operations at a
vaccines manufacturing plant.
1.1.1 Overview and Benefits of Value Stream Mapping in the Pharmaceutical Environment
A "value stream [is] the set of all specific actions required to bring a specific product or service
through the critical management tasks" [1]. In turn, a thorough understanding of the value
stream is imperative to effective operations, especially complex manufacturing such as those
required found during aseptic operations in the biopharmaceutical space. Such manufacturing
requires a precise understanding of how each step relates to another, the capabilities of each
process step, and the gaps between the current state and an improved future state. In part
because of these requirements, "value stream mapping is an effective and proven tool to assess
existing business processes and to re-design them based on "Lean" concepts" [1].
1.1.2 Value Steam Mapping Process Overview
Mapping the value streams of the aseptic segment required enough precision to have actionable
findings, yet be broad enough that the value stream mapping process could be repeatable and
continue to be updated without inordinate effort. To map the aseptic value streams, the segment
was divided by families of products that shared similar characteristics. From there, metrics were
standardized globally and data was collected for each line and family, respectively, to allow for
the new metrics to be measured. The current state value stream maps were then created allowing
for more in depth analysis. After determining significant and workable projects, a desired future
13
state could be envisioned. Finally, an improvement strategy for the short and mid-term projects
was created to convey a clear vision of expected improvements.
1.2 Value Stream Mapping Drivers
In an ideal world, managers and operators would know all aspects of their process allowing them
to make constant improvements to better the process. It would not be necessary to map out all
knowledge because it is already known and being acted upon. However, in reality, the aseptic
process inherent in all vaccine production is highly complex with numerous metrics and
variables to keep organized. In order to prevent the overly prevalent the "gut-based" decision-
making that comes when a clear understanding of the process is lacking, value stream maps are
required. Therefore, since the aseptic process had never been mapped, there was a significant
need.
1.2.1 Cost Drivers
Vaccine production is a commodity business, especially when contrasted with the closely related,
highly profitable, pharmaceutical industry. Unlike the more profitable "reactive" drug industry,
the preventative drug industry has historically low margins [2]. While new blockbuster drugs are
changing the shape of the industry and promising increased profitability, Novartis's potential
blockbuster (Bexsero) has yet to reach commercial operations [2]. Therefore, while the future
looks bright, current profitability is very low. This is clearly evidenced by the most recent fiscal
year, 2012, in which Novartis Vaccines posted a quarter billion dollar loss, 13.5% of sales. This
is trending average for the division over the past 2 years as Vaccines lost 249 million dollars in
2011 [3].
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Much of these losses are due to manufacturing losses and process failures as half of all batches
started are written off [4]. Since the vaccines division is one of the newest acquisitions to join
the company that has traditionally been able to turn a substantial profit based on research
excellence as opposed to manufacturing and supply chain excellence, the vaccines and
diagnostics division is in a unique place in the company in that operational excellence is key to
the vaccine division's profitability [3]. As an early step on the operation excellence journey, it
was recognized that in order to reduce losses, it was necessary to understand the specific sources
of the losses and the causes of the losses.
1.2.2 Capacity Constraints
The overwhelming consensus amongst managers and operators in the aseptic area is that demand
is outstripping capacity. While this perception of low capacity will be shown to have other
causes, the ability to get all products through the vial and pre-filled syringe lines at the
appropriate time remains a challenge. Some of the capacity issues are caused by an inadequate
planning process that causes frequent, and disruptive, schedule changes. Despite this, the
demand for aseptic services within the division is very high and looks to show significant growth
with the introduction of Bexsero because of its expected high sales volume [3]. While these
scheduling issues are very apparent on the surface with starvation, blockages, long queue times,
and extending cycle and lead times being the symptoms, the scheduling issue needs to be
addressed at its core with fundamental organizational and cultural changes.
1.2.3 Cultural Drivers
One of the most easily ignored, yet most important reasons for mapping the aseptic value stream
is to change the cultural norm of the Novartis Vaccines Division. Before the start of the project,
the culture was not one of relying on data. From the perspective of most managers on the shop
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floor, data represented mistakes and faults that might warrant punishment, not opportunities for
improvement and therefore accolades. The goal was, by mapping the processes, to show that all
areas have opportunities for improvement and give a path for improvement that is based on fact,
not gut or experience alone [5].
1.3 Problem Statement
The goal of this research is to create an implementable short to mid-term (3-5 year) strategic plan
for operations improvement and write-off reduction through the use of the value stream mapping
technique. Further, the project is designed to be the impetus for bringing about a full-fledged
value stream mapping program throughout the business through a culture shift from gut-based
decision making to a reliance on the data.
1.4 Thesis Structure
This thesis will begin with a review of the biopharmaceutical industry and will narrow scope to
Novartis, the division in question (Vaccines and Diagnostics), the specific site (Rosia, Italy), and
finally to the actual segment under consideration (aseptic). Following this overview, there is an
overview of the existing literate on value stream mapping techniques.
After setting the stage, the next two chapters deal with the specific approach taken to achieve the
final results. The methodology and results are discussed. This section explores the
interconnected nature of the issues seen in the aseptic area the underlying problems that exist.
Next, is an example of further analysis that was conducted that will serve as a baseline to a future
project to greatly reduce aseptic write-offs. This project is typical to those that should be
continued to implement all aspects of the strategy formulated with this research.
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Finally, the thesis concludes with the high level conclusions that can be drawn from the research
and recommendations for moving forward. It also draws in current projects that are currently
underway in Rosia in accordance with the strategic plan formulated in this thesis.
2 Biopharmaceutical Manufacturing Background
2.1 Novartis Group Background
Novartis is a very large pharmaceutical conglomerate reaching well over 1 billion patients on an
annual basis [3]. Novartis is also well known for its rich pipeline with over 200 new products in
clinical development [3]. The group has 6 major divisions: Pharmaceuticals, Vaccines and
Diagnostics, Generics, Consumer Health, Eye Care, and Research and Development. Primary
operations take place around the world while the company is headquartered in Basel, Switzerland
[6] [7].
2.2 Novartis Vaccines Background
Novartis Vaccines believes that "the only thing better than finding a cure for a disease is
preventing illness in the first place". Novartis Vaccines, now the fifth largest vaccine
manufacturer overall and the second largest producer of the influenza vaccine, came into being
following the Novartis acquisition of Chiron. The business is headquartered in Cambridge,
Massachusetts; however, most production occurs at facilities in Italy (Siena and Rosia), Germany
(Marburg), the United Kingdom (Liverpool), and elsewhere in the United States (Holly Springs
and Emeryville) with new facilities in the emerging markets of India, China, and Brazil [7].
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Novartis Vaccines employs 6122 employees in 30 countries and has annual revenue of 2.0
billion (3.4% of total group revenue) [8]. However, vaccines are viewed largely as a commodity
and therefore have low margins. In fact, the business operated at a loss in 2012 [3].
2.3 Innovation, Quality, Productivity (IQP) at Novartis V&D
Novartis Vaccine's lean six sigma journey began in 2007 when the Innovation, Quality, and
Productivity Group was formed. It initially was very small (with only one person) and has
grown steadily in number and vision in the past five years. The training of personnel (both black
and green belts) has been one of the cornerstones of the group since its inception. As can be seen
in the below diagram, the IQP group now focus to forward looking Operational Excellence
projects and improvements instead of retroactive/remediation type activities.
Dedicated Global FTEs: 1 2 5 4 6
Dedicated SiteFunctionFTEs 0 0 0 0 11
Figure 1: Novartis Vaccines Operational Excellence Journey 19]
In this diagram, FTE refers to "full time employees" and OE stands for "operational excellence".
Imbedding the use of value stream mapping and focusing on the data have also been strong
initiatives coming from the group with intensified focus since the close of 2011.
2.4 Overview of Aseptic Operations
Aseptic Operations are widely viewed as the most complex portion of the vaccine manufacturing
process. The term aseptic operations refers to manufacturing within tight air quality and sterility
specifications to ensure that product is not contaminated. While this significantly increases the
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complexity and costs of manufacturing, it is important to ensure that the drug product is safe to
be injected into patients. Specifications are set by the regulatory agencies of the product's
destination country and are organizations such as the US Food and Drug Administration (FDA)
and country specific ministries of health. Additionally, because Novartis is dedicated to
improving the lives of patients around the world, Novartis Vaccines has implemented additional
quality standards and controls in addition to the already strict government regulations that are
applied to the release of all vaccines. This is to ensure that all products released to the customer
are safe and effective and produce the best possible outcome for the patient. All aseptic
processes are strictly scrutinized making thorough documentation and certification of all process
steps critical.
2.5 Rosia Aseptic Operations
Rosia is the primary aseptic production site with most products passing through the facility. In
fact, the facility is designated the "center of excellence" for aseptic operations in the Novartis
network [10]. Rosia receives antigens, the active ingredient in most vaccines, from numerous
sites throughout the network creating a complex inbound supply chain. After receipt, the final
formulation occurs followed by the product being filled into prefilled syringes (PFS's) or vials as
shown in Figure 2. The outbound supply chain is much simpler as the primary customer
(packaging) is located on the same facility in a building that is physically connected.
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Formulation Filling
Aseptic Process
Figure 2. Significant Steps In The Aseptic Process Including Inputs and Outputs
Over 300 people work in the segment with many of the workers being on temporary contracts.
These workers mainly support the three primary PFS lines and the Vial line. There are other
smaller lines in the segment, but those are not the focus of the research.
2.6 Segmenting the Area for Value Stream Mapping
To obtain precise enough information to have actionable results from the value stream map, the
products were divided into product families a can be seen in the following figure:
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I
Product Family Key Characteristics
Adjuvant The adjuvant product family encompassed all non-flu products that
had an additive to modify the effect of the vaccine's antigen. The
most common adjuvant used in the vaccines produced by Novartis
Vaccines is Aluminum Hydroxide, known more commonly as Alum.
This accounted for nearly all products not related to Influenza
besides Menveo.
Flu with MF59 This product family encompassed all influenza preventing products
that contained the MF59 additive. MF59 is an adjuvant that is added
to the flu vaccine to increase the antibody and T-cell response of the
vaccine. In addition, the MF59 additive has been shown to increase
the cross-reactivity of the vaccine to virus strains not specifically
covered by the vaccine [11].
Flu without MF59 All influenza products without the MF59 additive are included in this
product family.
Menveo Menveo is a very complex meningococcal vaccine that protects
against four of the five most common strains of Meningitis that occur
in the United States. Because the vaccine protects against four
unique strains, there are four distinct proteins (antigens) that must be
blended into a single vaccine thereby increasing the manufacturing
complexity [12].
3 Review of Existing Literature Relating to Value Stream Mapping
This section will describe the established thought on Value Steam Mapping. While the exact
process for conducting a Value Stream Mapping exercise varies even between industry experts,
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general themes have emerged and the multiple methods, including those laid out in Mike Rother
and John Shook's Learning to See, and these have been synthesized below [13]:
1) Determine Product Families
The Value Stream Mapping exercise is greatly simplified by focusing on creating proper
families that share not only similar process steps, but also similar characteristics. Further,
by selecting homogeneous families, the benefit is maximized as the results are usually
more specific and therefore more implementable [14]. In the pharmaceutical
environment, it was found that other factors such as product consistency, drug function,
and season of production/campaign were very important to consider in the formulation of
product families.
2) Understand the Perceived Problem
It is important to understand the issues at hand from both the perspective of the process's
customer as well as other stakeholders within the organization [14]. The first primary
benefit from understanding the problem at multiple levels is that the value stream map
should include the correct metrics to address all the issues. For example, the customer
might not be concerned that the process has a large expected amount of waste built into
the product, but other stakeholders such as engineering, operations, and finance may see
this as an issue and an opportunity to improve yields and lower costs. Another significant
benefit in interacting with many stakeholders when determining the process's issues
pertains more closely to the practical matter of implementation. The creation of the
Value Stream Map requires the support of numerous departments and functions.
Through forming good working relationships with the personnel in these departments, it
is more likely that they will be willing to dedicate resources and time to complete the
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map. Further, by knowing all issues, the Value Stream Map is more likely to address the
primary causes for concern and understand connections between issues and, at the
conclusion of the process, solve these problems. In the end, solving problems about
which the stakeholders have expressed concern will create buy-in for further projects and
likely provide the best improvement for process efficiency, throughput, and productivity.
3) Walk the Value Stream
Gemba, the Japanese word for "actual place" is commonly used in the manufacturing
setting to denote that one must "go and see" to fully understand the process. Going to the
actual work site ensures that miscommunications on explanations do not occur, that those
creating the Value Stream Map understand the work environment and culture, and so that
people can see for themselves seemingly minor points that could be missed during an oral
explanation of the Process [1].
4) Collect Pertinent Data including Times and Key Metrics
From precious conversations with stakeholders, key metrics will be able to be identified.
Standardization of these metrics is important to ensure continued used and for
benchmarking and to ensure that all in the company are speaking the same language with
the same operationals definitions. After the metrics are identified, it is imperative to
ensure all data is either being collected or that the gap is identified so future data can be
obtained.
Data collection ideally will be based on physical observation whenever practical. In the
biopharmaceutical vaccine industry, it is often not practical to observe a process step
multiple times as each step can be many hours or days in duration. In this case, estimates
of the data should be provided by historic records or by the operators themselves [1].
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However, if using the estimates of the actual associates performing the action, it is
important to understand the biases that may consciously or subconsciously affect their
answers.
5) Draw the Map
The Value Stream Map should be drawn by hand. It is acceptable for later drafts for the
map to be made electrically, but it is not mandatory. Common technique is for the value
stream map to be drawn on large sheets of paper with adhesive notes to denote the data
for the process steps. This is done such that the actual map is accessible, not just a
document on lost in a computer system. The map should be created by all those who are
involved in a process, not just those with computer access. Additionally, the map should
be posted in a visible place such that it is frequently on the mind of those involved in
making the process, from operators to managers.
6) Identify Opportunities for Improvement/ Identify a Future State
After completing the map, it becomes necessary to focus on the key drivers of success
and to identify what will cause the greatest improvements. This could involve many
steps including challenging each step to determine which steps create value (and
eliminating steps that do not), attempting to achieve continuous flow wherever possible,
and leveling the value stream [14]. It is also important to identify the underlying causes
of problems and any interconnectivity that might exist between issues.
7) Create Strategy for Improvement Implementation
Because of scarcity (of resources, budget, and personnel), not all improvement ideas will
be implemented. For this reason, it is critical to create a prioritization method that not
only takes into account the effects of the improvement, but also the cost. When creating
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this strategy to reach the future state, the value stream mapper must design a future state
that can be achieved in a reasonable timeframe [1]. The appropriate time frame will
differ based on a number of factors (including industry, cash on hand, and company
culture), but one year is considered to be a reasonable timeframe [1]. In the
pharmaceutical industry, timelines are somewhat longer because of regulatory hurdles
and the campaign manufacturing nature of the business.
8) Repeat Cycle on a Regular Basis
Because the process will not be perfected after one Value Stream Mapping exercise, the
process must be repeated for the best results. Further, besides alerting managers to
potential improvements to their processes, value stream maps are valuable in that they
provide managers and operators the ability have a deeper understanding of the current
state of the process. Continuous mapping of value streams allows owners to know the
process deficiencies at all times and demands thorough understanding of the process.
4 The Methodology for Value Stream Mapping the Aseptic Process
This section describes the approach used for mapping the Aseptic Process at Novartis Vaccine's
Rosia Site.
4.1 Scope Definition
The original project scope was defined as being bounded by the four walls of the aseptic area,
but was narrowed to only include major products and those with the potential for long term
production. This meant that all products and processes within the aseptic area were within
scope. However, once it was discovered that a specific high volume product was being
discontinued in the next fiscal year, that product and its dedicated line were removed. Similarly,
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low volume products on lines other than the four primary vial and pre-filled syringe lines were
removed from scope.
The four wall approach includes scheduling and in-process inventory, but not the complete
supply chain or warehouse. The following SIPOC demonstrates the scope and the process's
customers and suppliers along with the overall scope. The name SIPOC is an acronym that
comes from the chart's function of clearly defining a process's suppliers, inputs, process,
outputs, and customers.
Suppliers Inputs Process Outputs Customers
-Supply Chain - Bulk Material -Decreased -Aseptic Head
(Primary) - Personnel Write-offs -Site Head
-Liverpool -Physical - Strategy -Packaging
-Siena inventory - Increased
-Rosia -Caps Profit Margin
-Marburg -Viles - Increased
' Aseptic Head -Syringes Throughput
' Site Head - Testing-data - Increased
' Maintenance collection Quality
Receive Bulk sanitize
Figure 3: SIPOC chart depicting the scope in context of suppliers, inputs, outputs, and customers
The SIPOC is useful to focus scope and to identify stakeholders. It is also useful in determining
who has influence to make changes or improvements for the process in question. In this
exercise, many levers were available to address the issues that were discovered during the value
stream mapping process, but some were off limits. This corresponded loosely to the span of
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control of the aseptic segment head which will allow for more effective implementation of the
improvement plan.
4.2 Hypothesis Generation
Following scope definition, it is necessary to determine potential causes of the scheduling and
process issues. First, a hypothesis tree was created to break down the high level concepts into
precise and actionable tests. The hypothesis tree can be found in the appendix. As a case study,
the hypothesis generation process started with a hypothesis such as "poor planning methods are
causing write-offs". From there, this general hypothesis is broken into more specific and precise
statements that can be tested. Continuing on this particular hypothesis, it was broken down as
can be seen in the following figure:
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I,
/
Unnecessarily large
buffers cause higher
inventory costs
Large buffers cause
product to expire
Small buffers cause
starvation.
.
Scheduling changes
causes waste
Inventory sits for a
long period of time
taking up capital
Inventory sits too
long in buffers and
expire
Complimentary
products expire as
they wait to be
processed
Inventory managers
hold additional
product because of
-frequent scheduling
changes which is
eventually written
off
Scheduling changes
occur after set up
has begun thereby
increasing costs
Figure 4: Hypothesis Generation Process
From the above figure, it should be noted the hypothesis transition from broad and general to the
more specific and actionable. The mark of an acceptable hypothesis is if, after answering the
question in either the affirmative of the negative, if there is a specific course of action that can be
completed to fix the issue.
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Scheduling
uncertainty cause
higher inventory
costs
Scheduling changes a
increase set up costs
4.3 Project Baseline
This section will describe the initial state of the organization before the project began. It will
help describe the motivations and need for the value stream map.
4.3.1 Current State of Data Collection
Data availability is critical to the successful implementation of a value stream mapping program.
However, prior to this research, there was very limited useful data as can be seen in the below
initial state value stream map representative of the Adjuvant Product Family (Figure 5). While
the specifics of this chart are not of specific importance (nor legible in this format), it is useful to
understand that red starburst indicate data that was not believed to be collected in any capacity
and that yellow starbursts indicate where data is thought to be collected, but stored in a restricted
or other difficult location that reduces its usefulness and accessibility. Larger starburst with
improvement suggestions were placed to correspond and provide additional detail on the missing
or lost data. In Figure 5, solid lines indicate product flow. Horizontal parallel lines indicate
separate lines with parallel flow. Notched lines (those that look like lightning bolts) indicate
electronic information flow and boxes represent process steps. Triangles indicate buffers and the
circle with a U beneath it represents the number of personnel in that particular area. The notched
line on the bottom (looks similar to the top of a castle) indicates value added time when the line
is raised and non-value added time when the line is in the lower position.
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Figure 5: Initial State Value Stream Map Displaying Missing Data
However, senior managers believed that a lot of the necessary data was being collected. This
disconnect had three major causes: the location of the data, a misunderstanding of what data is
important, and the manner in which the data was presented.
1) Much of the data was stored on personal spreadsheets instead of companywide databases.
While large data management software was employed, it was rarely used. In fact, often
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times the data stored in the data management software, such as SAP, was incorrect and
discounted. This led to those unfamiliar with the organization to use faulty data and for
insiders to collect data on their individual computers.
Based on the research and through numerous interviews, one person had a good
understanding of what data was collected and where. There were many instances in
which one manager would state that a particular set of data was not collected only to have
the next confirm that they did indeed have a spreadsheet on the computer. Conversely, it
was discovered that the same data was collected by multiple sources, such as on a
personal computer (or multiple peoples' computers) and in SAP. Often times, this data
was not in agreement and left questions about accuracy.
The result of unorganized data collection leads to data being collected without a purpose
and for those in need of data to analyze wanting. At first glance, data collected without a
direct outcome does not seem to have negative repercussions. However, data collection,
particularly in highly regulated industries such as the biopharmaceutical industry often
requires additional work by the operators. Operators will likely stop collecting quality
data if they do not see a benefit. Further, time spent on data collection is considered non-
value-added time. That is, the time spent collecting data is not directly adding any value
to the product and therefore should be minimized whenever possible. On the other hand,
when data is not available, the opportunity cost could be high as potential improvements
are foregone.
2) Because data collection decisions were often made the individual supervisor level, not at
a plant or global level, often important data is missed. Each individual supervisor could
fall into a tunnel vision that blinded them to potential improvements. For example, time
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data was not collected for certain operations (particularly in the formulation stage)
because the common believe was that the work done was too individualistic to be
improved overall. However, it is expected that by learning the operation time and
through analysis of trends, that best practices could be identified and spread throughout
the plant and business.
3) Finally, data was rarely displayed to those who needed to use it in a coherent manner,
such as the value stream map. It was therefore very difficult to use, compare, and assess
the needs. Data and analysis would appear to more senior managers during meetings, but
for those closer to the floor, it was rarely seen. In part because of this, each individual
line and segments within that line collected data in different ways according to what they
deem important and what is easiest for them: on separate spreadsheets, in nonstandard
formats, and without common metrics.
4.3.2 Current Decision Making Process
Because of the above mentioned data collection issues that existed prior to the value stream
mapping, there existed a culture of making decisions without analyzing the proper data. It was
common for gut instinct, experience, and preference to be the basis for changes. However, this
method contrasts directly with Lean, Six Sigma, and Novartis's own IQP (Innovation, Quality,
and Productivity) guidelines for project management which state that data should be used to
make all decisions [15].
4.3.3 A Culture of Data Hiding
Another significant aspect of the climate in the aseptic segment at Novartis Rosia was the
manner in which data that indicates a potential for improvement was viewed. Managers saw data
that indicated low performance as something that would be used against them, not as an
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opportunity for improvement. Instead of using data to show how the segment could become
better with potential rewards for improvements, it was seen as a cause for punishment and
negative marks. Since standardized data collection was minimal, managers did not have
motivation to display data that did not show their area of responsibility in a favorable light.
This manifested in managers not sharing their data with those who need to use it for proper
analysis. Since the data collection was typically local and contained within the individual's
computer, plausible deniability of the data existed sharing of the data could be prevented.
4.4 High Level Focus Factors
In order to confirm that the aseptic area had the most pressing write-off scenario out of all
segments in the business, overall write-off data was examined. The below Pareto chart shows
that the aseptic area (seen on the chart as "Tech Ops Aseptic") produces the most write-offs out
of any department in the business.
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Figure 6: Write-offs Broken Down by Department of Occurrence
The next step was to break down the aseptic write-offs to determine their most probable causes.
This served to provide a high level understanding of the source of the lost product. The
following figure shows that contamination, bioburden, and sterility failures cause the most write-
offs.
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Figure 7: Leading causes of write-offs
It is interesting to note that the top three causes of aseptic write-offs are all directly related to
process failures. This reaffirmed that value stream mapping was the optimal tool to determine
potential improvements as the technique is able to readily show process failures. Another key
observation from this chart is that human error ranks very low on the causes of write-offs. This
is because many human mistakes are wrapped up into other categories. Human error is a large
reason of issues with regards to the sterility of the process and the space, so it makes sense that
the contamination, bioburden, and sterility category, along with the EM (environmental
monitoring-measure of the sterility of the air in the aseptic space) excursions would outweigh the
specific human error category.
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5 Current State Value Stream Map and Analysis
This section is designed to display the findings from the value steam map and show the areas
selected for further analysis.
5.1 Current State Value Stream Maps
Below is an example of one of the value stream maps created with starbursts indicating identified
problem areas. Important sections will be highlighted below as Figure 8 is to provide a high-
level overview
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Flu withou MF 69 Product Family________
Figure 8: Current State Value Stream Map (Flu without MF59) with Issue Indicating Starbursts
The current state value stream maps served to aggregate all process data on a single location and
to make a standard way to display data throughout the segments. Because of these value stream
maps, a certain level of data is expected and that data can be easily compared to other similar
segments and otherwise benchmarked. The current state value stream maps were also presented
to many members of the aseptic area so all could see the data and their work. The figure above
(Figure 8) shows an example value stream map of the flu product without the MF59 additive.
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In this chart, similar to Figure 5, horizontal parallel lines indicate separate lines with parallel
flow. Notched lines (those that look like lightning bolts) indicate electronic information flow
and boxes represent process steps. Triangles indicate buffers and the circle with a "U" beneath it
represents the number of personnel in that particular area. The notched line on the bottom (looks
similar to the top of a castle) indicates value added time when the line is raised and non-value
added time when the line is in the lower position. Additionally, the key on the bottom right of
Figure 8 indicates the meaning for each of the colored starburst. For example, a red starburst
indicates that a particular metric indicates a problem in the batch record review process.
In this map, the specific numbers are unreadable due to proprietary concerns. However, for the
overall process, the following data box was filled to provide important overall performance
metrics to the entire product family through the process. These data boxes were standardized
throughout the company to make more uniform value stream maps.
Overall Performance
Metric Target Actual
Median Release Time
% Value Added Time
Total Minor deviations
Total Major Deviations
Total Critical Deviations
Total success rate
Total Schedule Adherence
LTI R
Total NVD staff
NVDTemps
Agency Temps
Figure 9: Overall Performance Metrics for Value Stream Maps
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Additionally, the same information was collected for each step and line in the process as seen
below:
Process Step Performance
Metric Target Actual
OEE
Availability
Capacity Utilization
Unplanned downtime
Changeover & Set Up Time
Performance
Cycle Time
Schedule Adherence
BPR Review Time
Quality
Write offs / lost batches
Step Yield
Minor, Major, Critical deviations per batch
BPR Right First Time
Figure 10: Process Step Metrics for Value Stream Map
As seen in Figure 10, it was especially important to find information that is useful in the
calculation of Overall Equipment Effectiveness (OEE) which meant focusing on availability,
performance, and quality.
Similar maps were created for all product families and can be seen in the appendix. At a high
level it was observed that the formulation stage of the process typically lacked data, that
calculating percent value added time (a valuable component of value stream maps) could not be
calculated due to a lack of time data, and that other issues fell into one of four primary
categories: data collection, scheduling, process robustness, and utilization.
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5.2 Analysis of Major Opportunities for Improvement
This section is designed to provide understanding of the four primary deltas that were observed
in the value stream maps. Color coded starbursts are used in the above figure (Figure 8) to
emphasize each particular category. A further breakdown of each category by line and product
will be shown below.
5.2.1 Scheduling
The below charts show the schedule adherence metric for 2012 in the aseptic area broken down
by both product and process step. Schedule adherence measures the ability of the process to
manufacture a specific lot within three days of the scheduled production date as of the latest
schedule revision.
Schedule Adherence by Product
Total Adjuvant Flu w/ Flu w/o Menveo Lyo Other
MF59 MF59
Product Family
* Overall (SAP) %
" Total %
Figure 11: Schedule Adherence by Product Family
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Figure 12: Schedule Adherence by Process Step
From these charts, there are two significant takeaways: low overall schedule adherence and
differing results for the same process.
First, overall adherence is around 50%-70%, depending on which metric is used (to be discussed
below). In other words, there is only a 50-50 chance that a scheduled batch will be
manufactured within three days (before or after) of its intended date of production.
While all schedule adherence is low, it is interesting to note that the type of product and process
step both have a significant effect on the schedule adherence. The data shows that campaigned
products (primarily both flu families) typically have a better flow than those that are not
produced in campaign. As flu products are the only products produced in large scale campaigns,
it can be seen that their respective schedule adherences are both higher than average.
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Additionally, since filling and inspection are often run continuously on the same line, their
adherences are similar, but lower than that of formulation. Variation in the formulation process
(including variation due to lower adherence upstream) is a cause of the low adherences in filling
and inspection.
Second, there are two methods of analyzing the data that show significantly different results.
This illustrates the before-mentioned data collection and data perception issues that resulted in
employees having private spreadsheets on their computers that complemented what is on a larger
database. In this case, SAP measures adherence differently than the employee responsible for
this metric. While the employee's method seems to be more correct based on an independent
overview of the methods used to obtain the data, the formula in SAP has not yet been corrected,
so only he has the correct information which severely decreases the data's usefulness. The red
bars (typically higher than the blue bars) are from the employee whereas the blue bars are
extracted directly from SAP.
These scheduling delays have negative consequences because disrupt labor planning, cause
materials waste, and cause an inconsistent output to the downstream manufacturing steps of
packaging and labeling. Operators are told of their schedule based on when their services are
required (different products have unique labor requirements) so a change in product can change a
schedule. This decreases employee satisfaction and increases frustration with the system.
Additionally, since changes are often made at the last minute, many materials (such as the piping
in formulation) have already been prepped for production by the time the change is made. Once
the set-up created, it much be used in a timely manner, or in the case of a schedule change,
scrapped. Finally, when conducting interviews with the aseptic segment's downstream
customer, the packaging segment, the chief complaint is that their operations schedule in a
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constant state of flux due to the inconsistent output from aseptic which causes their production
costs to increase.
5.2.2 Process Robustness
Most employees, supervisors and operators alike, believe that deviations are the cause of many
of the problems in the aseptic area. The data supports this observation in that deviations are very
common in the process. A deviation report is filed every time anything in the process deviates
from what is certified and planned. There are three levels of deviation (minor, major, critical)
depending on the severity of the deviation. The below figure shows the breakdown of deviations
by type over the first seven months of 2011.
2012 Deviation Reports by Type
Critico 12 Ma.rinrp 12 Minore 12 Grand Total 12
Figure 13: Breakdown of Deviation Reports by Type
43
From the above figure it is interesting to note that major deviations are expectedly much more
common than critical deviations, but unexpectedly more common than minor deviations. The
response procedures for critical and major deviations are much more complex making this
observation concerning. Going a level deeper, the below figure shows the number of deviations,
by type, over the first 7 months of 2011 and 2012.
DR's per Month by type (2011 v 2012)
-Critico 11
- Critico 12
-- Maggiore 11
- Maggiore 12
- Grand Total 11
- Grand Total 12
-- Linear (Grand Total 11)
Linear (Grand Total 12)
1 2 3 4 5 6 7
Month #
Figure 14: Breakdown of Deviation Reports by Type over Time
The above chart shows that, in 2011, deviations spiked at the start of the flu campaign
corresponding with an increase in throughput, but lessened as the campaign increased in
duration. In 2011, great attention was paid to this rise in deviations and therefore, with learning,
the number of deviations decreased. Conversely, in 2012, because of numerous urgent external
issues, personnel and resources were removed from the segment and therefore knowledge and
expertise was lost and the learning did not occur in 2012.
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DR's vs Write-offs per Month by type (2012)
Sum of Impact C
-- Critico 12
--- Maggiore 12
~ - Grand Total 12
E - Minore 12
January February March April May June July
Month
Figure 15: Write-offs by Month
The above chart can be used to test the hypothesis that deviations are a cause of write-offs. In
the chart the bars indicate the amount of each type of deviation for each month. "Critico"
indicates the number of critical deviations, "Maggiore" indicates the number of major deviations,
and "Minore" indicates the number of minor deviations in a given month in the aseptic area.
Due to scale, both January and May appear to be zero; in actuality, both these months had write-
offs near, but not exactly, zero. This is because a large amount of product that was reinstated in
comparison to what was written-off in those particular months. While there are not enough data
points to perform a multivariate regression, it does appear that there is a moderate correlation of
.368 between the number of critical and major deviations with the write-offs for that particular
month (as product is accounted as written-off very shortly after a deviation occurs, but can be
reinstated if the deviation is repaired). This correlation increases to .400 if minor deviations are
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excluded. From this, the conclusion that increased deviations, particularly major and critical
deviations, are a cause of increased write-offs can be drawn.
5.2.3 Process Efficiency
This section will show the low process efficiency with two metrics: utilization and overall
equipment effectiveness.
5.2.3.1 Utilization
Poor schedule adherence and constant process problems preclude the aseptic process from
running at it full efficiency. Process efficiency was measured in two ways: with the utilization
metric and with overall equipment effectiveness (OEE). It is important to note that there is no
utilization or OEE data for formulation because time data is not collected in the formulation
division based on the incorrect theory that the process is too individualized to be improved.
Additionally, insufficient data exists to measure the OEE for the inspection lines and for Line 2's
inspection utilization and OEE. The below figures (Figure 16: Utilization for each Inspection
Line and Figure 17: Utilization for each Filling Line) show the utilization of each of the filling
and inspection lines.
46
Inspection Utilization Comparision Across Lines
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Figure 16: Utilization for each Inspection Line
As can be seen in Figure 16, the inspection utilizations are very low, in part because the
inspection machines follow the bottle neck in the process, the filling machines. Since the rate of
the inspection machines is much greater than the machines that precede them, the inspection
machines experience starvation. Starvation can occur when processing rates of individual
machines are different or if there is an improper amount of work in progress. This means the
inspection machines have non-value added time in which they are not be utilized waiting for
product meaning that expensive capital assets are being left idle and not being used to their full
potential.
Utilization is defined by the number of syringes or vials that were produced divided by the
number that could theoretically be produced. In this case and below in Figure 17, production
refers to the number of units inspected, production refers to the number of units filled. The
number of units produced was determined by examining the production records while the
theoretical maximum number of units that could be produced was determined by finding the
number of working hours per day multiplied by the certified production rate.
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Filling Utilization Comparision Across Lines
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Figure 17: Utilization for each Filling Line
Filling utilization was calculated based on the theoretical number of units that could be produced
compared to the actual number of units produced, taking into account time lost due to breaks,
meals, and meetings. The biggest single reason for the low utilizations, however, was running the
machines at substantially less than validated speed. The filling machines are running, on average
between half and three-quarters of their approved speeds. Throughput could in greatly increased
by finding and addressing the root cause of the slow machine speeds. The initial hypothesis is
that the aging machines are no longer able to keep high speeds because a lack of preventative
maintenance or simply because the machines are relatively old. According to aseptic managers,
the amount of additional product that would be written-off running at high speeds would be
greater than any incremental profit gains. Since the vaccines are typically not demand
constrained (meaning that there is more demand than supply), increasing throughput should
directly increase revenue and profit.
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5.2.3.2 Overall Equipment Effectiveness
Another measure of system performance is overall equipment effectiveness. This metric is
defined by Novartis Vaccines as "a total measure of performance that relates the availability of
the process to the productivity and quality" [15]. OEE takes into account the availability,
performance, and quality of the process. Availability takes into account equipment breakdowns
and set-up/adjustment times, performance measures process speed and small (micro) stoppages,
and quality looks at the defect rate along with other losses that lead to reduced yield (such as
startup losses stoppage losses). The below figure also illustrates these factors relationship in the
metric [15]. For example, starvation would cause stoppages and decrease the "performance"
metric.
Availability Dowbsw
Performance
Defec-tkrbse
r~]L~i
EScheduleddowntime
Idle Time from
Non-Use
(Scheduled
Downtime)
Breakdowns
Stoppages Setups
Slow Speed
Starvation
Blockage
Defects
Setup losses
Figure 18: Visualization of Overall Equipment Effectiveness
The actual formula for OEE is as follows:
OEE = Availability x Performance x Quality
Equation 1: Overall Equipment Effectiveness
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Scheduled Time
Total Time
Qualli A- -XY
and can be broken down as follows with each of the three metrics of OEE (availability,
performance, and quality) is bounded by 0 and 1:
Scheduled Time - Downtime # of Units Produced x Ideal Cycle Time Input - Defects
xxScheduled Time Actual Runtime Input
Equation 2: Overall Equipment Effectiveness Formula Breakdown
Where "scheduled time" is the time during which the equipment was expected to operate,
"downtime" includes breakdowns and set-up and clean-up time, "# of units produced" refers to
the number of units produced in a cycle, "ideal cycle time" is the designed cycle time, "actual
runtime" is the scheduled time minus downtime, "input" is the number of units that started the
process, and "defects" is the number of defects (including those that underwent rework to be
salvaged). The middle term above is the most complicated and should be thought of in terms of
a shift with the numerator being the minimum (best theoretically possible) amount of time
required to produce the units produced in that shift and the denominator being the time of
production. The numerator provides the minimum theoretically possible runtime possible and
since this number is not achievable in practice, the term will never exceed 1 and, since the
product cannot be negative, the term will never be less than 0. Further, the term is dimensionless
as the numerator's units are time (# of units * # of its yields "time" as the sole unit because
the "# of units" terms cancel) and the denominator, runtime, is also in time. OEE is commonly
expressed as a percent by multiplying the final value obtained from the above formula by 100.
Because OEE is the product of three factors, the OEE score will be lower than any single metric.
The OEE for the Rosia Aseptic area's filling lines can be seen below.
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Figure 19: OEE for the Aseptic Filling Lines
As can be seen from the above figure, OEE's are much lower for the vial line and line 3. One
significant factor is that line 1 is typically run around the clock operation whereas the other lines
are not. This reduces urgency and causes line 1 to be prioritized to ahead of the other lines.
5.2.4 Batch Record Process
The batch record review process is the final major problem area identified in the value stream
map. Batch records are one of the most critical operations for manufacturers of
biopharmaceuticals as they are mandated by the FDA and other ministries of health. They are to
be a complete master production record for each batch that is produced. A batch is defined by
21 CFR Part 210 as "a specific quantity of a drug or other material that is intended to have
uniform character and quality, within specified limits, and is produced according to a single
manufacturing order during the same cycle of manufacture." This means that multiple batch
records must be generated each day since multiple batches are being processed within the aseptic
plant. According to good manufacturing process, a batch cannot be released for sale until the
batch record is completed and certified [16].
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Because products cannot produce revenues until the batch record is completed, it is vital that
there be a good process in place to ensure that they are completed correctly and efficiently.
There are two primary metrics that are used to describe batch record review (BPR) performance.
The first one is "right first time" which is typically expressed as a percentage of batch records
that make it through the verification process without requiring rework. Because each correction
much be made by a specific person, mistakes often prove to be difficult to correct and add
significant non-value added time to the process. The second metric is "batch record review
time" which measures the amount of time from the start of the process until the batch record is
completely approved. There are many reasons that review times are higher than desired
including poor quality/production integration and batch records requiring rework.
In general, the research found a direct relationship between the review time and right first
metrics. This is displayed in Figure 20 below.
Batch Record Review Time vs Right First Time
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Figure 20: Batch Record Right First Time vs. Review Time by Month
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This pattern is also repeated, though not as strongly, on a product by product basis as seen in the
below figure.
BPR Right First Time compared to Review Time
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Figure 21: Batch Record Right First Time vs. Review Time by Product
This relationship indicates that the primary reason for long batch record review times is rework
and a poor rework process. The high right-first-time rates are achieved by adding additional
reviewers in the process so that it is unlikely that an error would pass to the quality assurance
reviewer. However, because this is just lengthening the process, it causes the review time to
never decrease to goal levels (one day). Even the minimum acceptable level of one week is not
met during any month indicating that there are both process and rework process failures.
The data therefore indicates that, in order to solve these two correlated metrics, alternate methods
must be used as increasing inspection layers during the review process does not solve both
issues. A potential solution is to better integrate quality during the batch record creation. Instead
of having quality assurance (QA) act as an outside organization, they should partner with
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production as the document is being drafted to prevent mistakes while it is easy to correct them,
as opposed to waiting until the draft is completed.
The data can also be viewed by process step as seen below in Figure 22.
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Figure 22: Batch Record Review Time by Process Step
There are two important takeaways from this chart. First is that Menveo does not follow the
same pattern as the other products. This is because Menveo is seen to have a higher value
(because of its higher margin) and is therefore prioritized above all other products. This further
indicates that the current review process cannot handle the volume of batch records that must be
handled.
The other major takeaway is that the farther a batch is into the process (for example: inspection
vs. formulation), the longer the review time for that process step's batch record. Unfortunately,
this is the worst time for the delays as the product has a higher worth as it gets closer to
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completed which increases holding costs. Additionally, because late delays are more likely to
cause a delay in shipment since they occur closer to the ship date, there is an opportunity cost of
missed revenue.
5.3 Root Cause Analysis
After investigating the primary issues, the next step is to identify the root causes. The below
diagram was created to link the symptoms to their underlying effects. This diagram was created
by showing the symptoms and their underlying problems on the same page, then linking causes
and effects to show relationships.
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Figure 23: Interconnected Nature of the Current Problems
The above diagram shows that many of the symptoms that are seen in the process (such as
insufficient data collection, poor schedule adherence, too many deviations, batch record delays,
and process inefficiencies) have similar underlying issues such as a lack of feedback mechanisms
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in the process and from worker to supervisor, poor communication of goals and current state, and
insufficient training. It was found that, while it is good news that the issues are interrelated,
large companies such as Novartis expect to see immediate results and often do not have the
"patience" to attack the underlying issues. Figure 23 presents the argument that in order to make
the changes that will have large scale immediate results; the underlying organization issues must
be first addressed.
In this diagram it can be seen that there are many issues in the process, with one of the most
significant being scheduling. This manifests itself in the blockages and starvation (Figure 19
shows the low filling lines for the process which are, in part, attributed to blockages and
starvation). Additionally, the scheduling issues seen as the work in process inventory is very
high and because product spends a large amount of time in queues (product has been scrapped
because inventory sits in queue past its expiration date) and because cycle times are very high
(weeks are allotted for a one day process). This process cannot be fixed by tweeking parameters
or changing an algorithm, but must be addressed through cultural change. This cultural change
will, as is shown in the following sections, needs to address to feedback, communications, and
other fundamental issues before directing making changes to the scheduling process.
5.4 Issue Prioritization
To sort the problems facing Novartis and provide an actionable plan of attack, the improvement
projects need to be prioritized against a common metric, in this case an adaptation of the United
States military's CARVER matrix [17].
5.4.1 The CARVER Matrix
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The goal of the CARVER matrix, in the military sense, is to "achieve victory by inflicting the
greatest damage on your enemy with the least amount of resources" [17]. Similarly, in the
biopharmaceutical environment, the goal is to produce the greatest number of vaccines to help
patients with the lowest cost. In this case, cost includes monetary costs, resource utilization,
human capital utilization, and good-will costs. In other words, this framework is designed to
prioritize to achieve the highest efficiency, leanest process possible [17].
The adapted elements of the CARVER matrix can be seen below in Figure 24.
Economic
feasibility (will
it fit in the Vulnerability
budget?) (How quickly
can we see
results?)0
Accessibility
(Are there
prerequisites?)
(nhftnar cthe
ProEliato
and Plnnn Eofnnil
ef ects
Figure 24: CARVER Matrix for Prioritization Adapted for the Biopharmaceutical Industry
5.4.2 Application of CARVER Prioritization
Once defined, the elements need to be applied to the results from the value stream mapping
exercise. Cause and Effect Matrices were used for this purpose in which each project was
assigned a score corresponding to each of CARVER's seven elements. In each matrix, each of
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Project
compatibility
(Will projects
have synergies
or overlap?)
Resource
Availability (o
we have
sufficient tools
and people?)
(Wha ar the
the factors was assigned a relative importance to the other factors. For example, "effects" had a
higher priority than "accessibility" and therefore a high score in "effects" carries more weight
than one in "accessibility". The matrices were broken into projects with long term horizons that
had short term prerequisites and those that needed to be (or could be) completed in the short
term. The matrices can be found in the Appendix.
5.4.3 Prioritization Results
After each project was evaluated on the based on all seven dimensions, they were prioritized as
seen below in Figure 25 and Figure 26. The prioritization graphs were an output from the cause
and effect matrices produced based on the CAVER prioritization analysis. In the cause and
effect matrix, each factor was multiplied by its relative importance and then summed across the
project to determine a final prioritization score which was, in turn, used in the creation of the
prioritization graphs.
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C&E Prioritization
Figure 25: C&E Matrix Short Term Prioritization
From Figure 25 it is apparent that the high impact short term projects are ones that involve
organizational fixes and root cause analysis whereas it will be seen below in Figure 26 that the
long term solutions attack the problems that are apparent on the surface. The short horizon
projects represent methods to solve many of the underlying issues that are causing issues. Based
on the above figure, Novartis has implemented a comprehensive realignment and is instituting a
new, exhaustive Value Stream Mapping initiative. Also in progress are DR reduction projects,
increased schedule monitoring, and environmental excursions reduction projects.
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C&E Prioritization
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Figure 26: C&E Matrix Long Term Prioritization
The long term solutions, like those presented in Figure 26 represent ways to sustain the solutions
that were created in the short term. For example, once the root cause of the scheduling issues is
fully identified, an algorithm should be implemented that takes into account all issues. However,
without the baseline knowledge to create relevant inputs, the computer program would be of
limited value.
6 Filling Volume Target Analysis
The following section will show an analysis of a high impact short term project as determined
through the value stream mapping exercise and the subsequent prioritization technique detailed
above.
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6.1 Filling Process Overview
The filling process is dominated by strict regulations and is a critical step in the production of a
vaccine.
6.1.1 Overview of Filling Challenges
Vaccines must be filled in to vials or syringes very precisely and at very rapid rates in order to
meet production goals. Since the vaccine is being administered to human patients, there is little
room for variation in the amount of drug in each vial or syringe. In fact, most vaccines must be
filled plus or minus 3.5% or 2% of the stated volume. Tolerances have decreased over the years
as filling equipment has improved. For example, one of the flu vaccines is sold in .5ml doses
meaning that, even with 3.5% tolerance, the acceptable filling range is very small: between
.4825ml and .5175ml [18].
6.1.2 Motivations for Improvement
When regulations were less strict, the old method of determining a filling target was not to select
a target in the center of the range, but instead something less thereby allowing the vaccine
manufacturers to fill less product on average, into each vial or syringe. Over long time horizons,
this amounted to large savings for the manufacturer. This was possible because the machines
were very precise in comparison to the filling volume windows. However, now that tolerances
have decreased and the machines have stayed largely the same, these misplaced targets are
causing significant waste. The following figure shows how a typical set of specification limits
looked in the past:
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LS] USL
Figure 27: Past Filling Specification Limits
Where LSL means lower specification limit and USL is upper specification limit. In the
situation shown in Figure 27, the filling target can be placed lower than in the center of the LSL
and USL as the spread is sufficiently tight in comparison with the specification limits (in effect,
high Cp). However, more modem specifications are tighter and make the spread appear as below
in Figure 28 since the distribution did not get any tighter, but the specification limits have
become tighter. Any shift of the target away from center (as seen in the Figure 28), will cause
the distribution to be outside the tighter specification limits, thereby increasing the likelihood of
product filled incorrectly.
LSL USL
Figure 28: Modern Filling Specification Limits
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All product that is filled outside of specification limits must be discarded because these limits are
set in accordance with FDA and other agency guidelines. Elimination of this waste could save
the company significant money as all vials and syringes that are outside the target filling range
must be discarded and written off as a loss.
6.2 Capability Analysis of the Filling Lines
A comprehensive capability analysis of the filling lines at the Rosia plant was performed to
determine if the any filling issues were present.
6.2.1 Capability Analysis Definitions
At a very high level, a capability analysis is performed to determine if a process is statistically
able to complete the required tasked within a defined set of specifications. There are two
important statistics that a frequently used in capability analyses: Cp and Cpk. C, is used to
determine the tightness of the cluster of data points and is calculated as seen in the below
formula [19]:
Upper Specification Limit - Lower Specification Limit
CP 6a
Equation 3: Calculation of Cp
Using the analogy of a car parking in a garage (where the garage width is defined by the
specification limits), Cp can be thought of as the width of the car. In this analogy, the car
represents the width of the normal distribution. If the car (distribution) is too wide, then the car
will not fit in the garage and, if the driver still tries, the sides of the car will be scraped.
Conversely, a motorcycle (thin) will fit very effectively as can be seen in the below figure.
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Figure 29: Illustration of the Process Capability Analogy for Cp [151
Similarly, a distribution with a large standard deviation will not be able to fit within specification
limits and the edges of the distribution will be lost to scrape (as they are outside the
garage/specification limits). The location where the car is parked is defined by the Cpk; is the car
in the center of the garage or off to the left or right? When parking the car, it is important to not
only have a car that fits, but to drive it to the center of the garage or there could be an accident or
it could miss the garage completely as seen below.
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Figure 30: Illustration of the Process Capability Analogy for Cpk [151
For the distribution, without proper targeting, even a tight distribution (high Cp) could be outside
specification limits. In this way, the Cpk measures the accuracy and precision of the data points
and is calculated as the minimum of the CpL and the Cpu which measure how much of the spread
is above or below the limits as seen in the following formulas [19] [20]:
U Upper Specification Limit - Sample MeanCpu- =c 3a-
Equation 4: Calculation of CpL
CPL - Sample Mean - Lower Specification Limit
3a-
Equation 5: Calculation of CpL
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Cpk = Min(CpL, Cpy)
Equation 6: Calculation of Cpk
In the above formulas, aY represents the sample standard deviation. Generally, 1.33 is seen as an
acceptable value of Cpk and Cp and anything below one indicates significant problems. With
knowledge of the combination of Cpk and Cp, one could have a strong understanding of the
expected short term performance of a process as these metrics can tell a manger the both the
accuracy and precision of a process. From this knowledge, the financial repercussions can be
identified (as will be show in the following section).
6.2.2 Filling Line Results
A capability analysis was performed on each of the filling lines. For the capability analysis, it
was determined that the process was both in control and resembled a normal distribution as can
be seen in this example graph below. For the example graph below, the C, is 1.31 and the Cpk is
1.27.
LSL Target USL
1211 0,582 0,588 0,594 0,600 0,606'0,612 0,618
Figure 31: Process Capability Graph of Flu Product [21]
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While it is clear that the process has low kurtosis compared to the standard normal, it is very
minimally skewed and appears to follow a bell shaped curve. After testing the assumptions, a
capability analysis was performed for the major products across the four lines as can be seen
below in Figure 32.
Tick Borne Encephalitis product
Tick Borne Encephalitis product
Tick Borne Encephalitis product
Figure 32: Summary Results of Capability Analysis on Filling Lines [211
As can be seen from the above figure, there are many filling lines that are below 1.33 and are
therefore not performing to expectations. Red indicates a Cpk or Cp that is less than 1, yellow
indicates a Cpk or C, that is between 1 and 1.33, and green is for all scores above 1.33 going
with common technique that red indicates problems, yellow indicates that the standard is not
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met, and green shows that the standard is met. By repositioning the targets, it was hypothesized,
and eventually shown that significant money could be saved with relatively low risk and
financial costs.
6.2.3 Financial Benefits to Repositioning Filling Target
To test the hypothesis that profit was being sacrificed because of the misplaced filling targets, a
simulation was run to compare the current write-offs to those that would occur with improved
filling targets. This was accomplished by simulating that the clusters of data points were
centered on the center of the specification limits. Overall, it was found that over $557,000 could
be saved annually by readjusting the filling targets, even when the difference in volume of filled
product was taken into account. Fluvirin filled on Line 3 yielded the greatest gains. For this
particular product, 10,500 parts per million are currently defective as indicated by a Cpk of .86.
However, with target realignment, the Cpk would increase to 1.41 and the defect rate would
decrease to 24 parts per million. Since approximately 4.4 million doses were attempted to be
filled (successfully or unsuccessfully) in 2011, the number of defective doses decreased by
46,381.
It is interesting to note that the below figure shows that much of the savings is concentrated with
relatively few products. In fact, approximately $400,000 (7 1%) in savings is able to be achieved
by only focusing on the three most influential product/line combinations.
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Figure 33: Expected Savings be Adjusting Filling Targets based on 2012 Simulation
The amount of impact is a function of throughput, cost of product, and prior C~, and Cpk values
and could vary based on product selection in future years. However, it is clear that a lot of money
can be saved with minimal effort by reevaluating the filling targets.
7 Conclusions and Recommendations
From the analysis performed, several important actions are recommended to improve the
performance of the aseptic area in Rosia and some have already been implemented.
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7.1 Strategy Implementation
It is recommended that the strategy laid out in Chapter 5 and found in Figure 25 and Figure 26 be
implemented immediately to achieve more immediate results. By immediately starting the long
process of changing the culture, it will allow for the foundation that allows for implementation of
symptomatic fixes be built more quickly.
7.1.1 Cultural change
Many of the highly ranked short term projects deal with organizational and cultural changes.
The division needs to make a significant commitment to changing the way decisions are made
and how data is collected. As can be seen in Section 7.2, there are currently several projects
underway. It is recommended that this continue and new projects begin. In order for this to
happen, all black belt positions must be filled. Currently, while it is directed that 1% of the
entire manufacturing force be dedicated to Operational Excellence as a Black Belt, this is not the
case and the Black Belts are overwhelmed. This is also important to create a community of
people working on Operational Excellence to provide more weight behind their
recommendations.
While bolstering the Black Belt ranks will be a good place to start, there are other actions that
will have positive effects as outlined in the strategy in Figure 25: C&E Matrix Short Term
Prioritization and Figure 26: C&E Matrix Long Term Prioritization such as realigning the
organization to have clearer accountability and reasonable scans of control, implanting value
stream for all segments, and finding the root cause to many of the problems through data. These
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actions will signal a cultural change that will be gut based decisions will no longer be accepted
and data must be used to back up conclusions and recommendations.
Additionally, by having data readily available (through value stream maps and data collection
improvement projects), data will no longer be able to be hidden on personal computers without
anyone outside a specific organization able to view it. The current culture of hiding data that
indicates room for improvement stifles creativity and covers up opportunities. By showing data
and metric performance freely, managers will be more inclined to address the low points by
implementing improvement projects.
7.1.2 Organizational then symptomatic
It will be very important to not be tempted to tackle symptomatic problems without first building
a cultural and organization foundation that can support and sustain these improvements. The
symptomatic problems will be high visibility and will tend to have large, measurable gains, but
their results will quickly disappear if the organization is not ready for them. This can be seen
with a recent LGO Batch Record Project that was initiated to increase right first time rates and
decrease response times. While the results of this project were exceptional (increased right first
time to above 95% and decreased review time to 2.5 days), the results have fallen off to what we
see today (approximately 85% and 21 days, respectively) [22]. By building a strong foundation
for these projects, the sustain phase will be easier and much more likely to become engrained in
the business's fiber.
7.2 Current Projects
In accordance with the value stream mapping exercise, there are numerous projects currently
under way at Novartis. Of note, two significant projects look to change the culture of the
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organization: realignment and value stream mapping. The Italy sites (Siena and Rosia) are
undergoing a comprehensive restructure to clarify responsibilities and accountabilities. This will
serve to increase productivity as communication, personal attention, and feedback will be
increased. Additionally, the Global Operational Excellence team has implemented value stream
mapping for all processes with monthly review meetings and standardized metrics. This will
push to increase data visibility and clarify process performance and goals.
In addition to these projects, other projects are in process to diagnose root causes (in particular,
for the scheduling issues and environmental monitoring), to develop a preventative maintenance
plan, and to continue with realigning the filling targets. These projects will build off the
foundation of the new organizational structure and the value stream maps.
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9 Appendix
9.1 Schedule Adherence
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Scheduling Performance Since Start of 2012
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
Overall data Overall batches planned 2145 441 92 1002 63 331 216
Overall batches performed (SAP) 1042 205 42 531 31 84 149
Total batches completed 1494 330 50 793 54 127 153
Overall (SAP) % 418.58% 0 46.49% 0 45.65% 4 52.99% W9.21% 25.38% C68.98%
Total % 069.75% 0 62.12% O 84.00/ 66.96% &7.41% 6.14% 07.39%
Filtration batches planned 570 139 0 421 0 10 0
Overall batches performed (SAP) 188 38 0 150 0 0 0
Total batches completed 509 120 0 380 0 9 0
% with rule +/-3gg (SAP) 2.98% 0 27.34% 0 35.63% 400.00%
% without rule +/-3gg 069.30% 0 86.33% O 90.26% C0.00%
Formulation batches planned 439 87 21 97 18 17 199
Overall batches performed (SAP) 310 54 13 80 15 7 141
Total batches completed 331 64 14 79 15 12 147
% with rule +/-3gg (SAP) 070.62% 0 62.07% 4 61.90% 0 82.47% C83.33% W1.18% 070.85%
% without rule +/-3gg 075.40% 0 73.56% 4166.67% 0 81.44% 083.33% 070.59% 073.87%
Filling batches planned 532 100 31 238 21 129 13
Overall batches performed (SAP) 233 57 14 155 0 0 7
Total batches completed 296 71 19 167 19 16 4
% with rule +/-3gg (SAP) &3.80% 0 57.00% 045.16% 0 65.13% 10.00% 40.00% 3.85%
% without rule +/-3gg 5.64% 0 71.00% 061.29% 0 70.17% (0.48% L2.40% &0.77%
Inspection batches planned 604 115 40 246 24 175 4
Overall batches performed (SAP) 311 56 15 146 16 77 1
Total batches completed 371 75 17 167 20 90 2
% with rule +/-3gg (SAP) 11.49% 0 48.70% V 37.50% 59.35% 6.67% &4.00% 25.00%
% without rule +/-3gg 1.42% 0 65.22% 042.50% 67.89% C93.33% 51.43% 0.00%
9.2 Deviation Reports
Formulation (total)
Critico
Maggiore
Minore
(blank)
Filling (total)
Critico
Maggiore
Minore
(blank)
Inspection (total)
Critico
Maggiore
Minore
Other (total)
Critico
Maggiore
Minore
(blank)
Other (QC) (total)
Critico
Maggiore
Minore
(blank)
Grand Total
Critico
Maggiore
Minore
(blank)
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9.3 Process Efficiency
The following show a breakdown of each line's efficiency by product family.
9.3.1 Line 1
Downtime due to Maintenence stops
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS1 00:24:22 00:12:00 00:24:00
Downtime between Set-up and Production (minutes per batch)
Total Adjuvant Flu w/ MF59 Flu w/o MF59 f Menveo Lyo I Other
PFS1 00:19:18 00:19:30 00:12:36
Downtime between Production and Cleaning (minutes per batch)
Total - Adjuvant I Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS1 01:12:12 01:17:30 00:39:02
Ttal Unplanned Downtime Time
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PF51 1:55:53 01:49:00 01:15:38
Changeover time (End of Production to the end of ceanIng+start of set-up to start of production)
aTotal FAjvant lu w/MF59 Flu w/o MF59 Menveo LYO Other
PFS1 04:4155 04:4645 :4121
Cycle time (Start of set-up to the end of deaning)
Total Adjuvant Flu w/ MF59 Fluw/oMF59 Menveo Lyo Other
PFS1 16:30:16 17:58:45 15:51:51
oIEE 7 mne y OtrTotal Adjuvant Flu w/ MF59 Fluw/oMF59 Menveo Lyo ther
PFS1 60.7% 68.1% 56.4% 1
Inspection Cycle Time
Total Adjuvant Flu w/ MF59 Fluw/oMF59 Menveo Lyo Other
PFS1 13:19:21 13:3130 13:17:55
EF~ling Time
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS1 11:14:35 13:12:00 10:41:53
Inspection Utilization
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo . Other
PFS1 34.53%
Filling Utillization I
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS1 44.84%
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9.3.2 Line 2
Downtime due to Maintenence stops
Total Adjuvant I Flu w/ MF5 lu w/o MFS Menveo Lyo I Other
44.61 PFS2 00:44:36 00:46:21 00:15:00
Downtime between Set-up and Production (minutes per batch)
I Total I Adjuvant I Flu w/ MF571u w/o MF5I Menveo Lyo Other
PFS2 00:05:47 00:05:46 00:06:00
Downtime between Production and Cleaning (minutes per batch)
Total Adjuvant Flu w/ MF5 lu w/o MF5I Menveo Lyo Other
PFS2 00:33:50 00:34:21 00:25:00
Downtime between Cleaning and CIP/SIP (minutes per batch)
Total Adjuvant Flu w/ MFSlu w/o MF Menveo Lyo Other
PFS2 01:03:25 01:07:22 00:00:00
Total Unplanned Downtime Time
Total Adjuvant Fluw/ MF5qluw/oMF Menveo Lyo Other
PFS2 02:27:37 02:33:51 00:46:00
Changeovertime (End of Production to the end of cleaning+start of set-up to start of production)
Total Adjuvant Flu w/ MF5 luuw/oMFJ5 Menveo Lyo Other
PFS2 08:33:39 09:05:45 1 00:00:00
Cycle time (Start of set-up to the end of cleaning)
Total Adjuvant Flu w/ MF5 lu w/o MF5 Menveo Lyo Other
PFS2 9:24:33 19:2546 19:04:00
OEE
Total Adjuvant Fluw/ M w/oMF5 Menveo I F5 Lyo Other
PFS2 issig mising missing
Inspection Cycle Time
Total Adjuvant Flu w/ MF lu w/o MF51Menveo Lyo Other_
PF 04:06:00 102:53:00
Filling Time
Total Adjuvant I Flu w/ MF5Jlu w/o MF51 Menveo I Lyo IOther
PFS21 12:18:57 1 112:08:35 115:15:001 1
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9.3.3 Line 3
Downtime due to Maintenence stops
Total I Adjuvant I Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
14.88 PFS3 00:14:28 00:14:28
Downtime between Set-up and Production (minutes per batch)
I Total I Adjuvant Flu w/ MFS9 Flu w/o MF59 I Menveo I Lyo Other
PFS3 00:32:49 00:32:49
Downtime between Production and Cleaning (minutes per batch)
Total Adjuvant Fluw/MF59 Fluw/oMF59 Menveo o 7 Other
PFS3 01:23:49 01:23:49
Downtime between Cleaning and CIP/SIP (minutes per batch)
I Total I Adjuvant Flu w/MF59 Flu w/o MF59 Menveo Lyo Other
PFS3 01:21:37 01:21:37
Total Unplanned Downtime Time
Total Adjuvant Fluw/MF59 Flu w/oMF59 Menveo L Other
S3| 03:32:4 03:32:42
Changeovertime (Endof Productionto the endof cleaning+startof set-up t rtaof production)
I Total Adjuvant Flu w/ M59 Fu w/o MF59 Menveo Lyo Other
PFS3 1039:44 10:39:44
Cycle time (Start of set-up to the end of cleaning)
Total Adjuvant Flu w/ MF59 Flu w/o MF59 T Menveo Lyo Other
PFS3 12:42:16 12:42:16
QEE
Total Adjuvant Flu w/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS31 28.1% 1
FinlnylenfTime
Total Adjuvant Flu w/ MF59 Flu w/o MFS9 Menveo L Other
FS31 11:06:51 1. Q5
Fill ngTirn~
I Total IAdjuvant Fl wl M MF59 Fluw/ Me~F9I Menveo I Lyo Other
PFS3 09:16:56 09:16:56
Inspection Utillization
Total Adjuvant Fluw/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS3 16.43%
Filling Utllization
Total Adjuvant Fluw/ MF59 Flu w/o MF59 Menveo Lyo Other
PFS3 18.36%
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9.3.4 Vials
Total
27.00 Vial 00:30:1
Downtime b
Total
Vial 00:39:16
Downtime between Production and Cleaning (minutes per batch)
Total Adjuvant Flu w/ MF5lu w/o MF Menveo Lyo Other
Vial 01:05:21 01:02:15 01:19:30 00:49:27
Total Unplanned Downtime Time
Total Adjuvant Flu w/ MF5Jlu w/o MF51 Menveo Lyo Other
Vial 02:14:55 02:03:45 03:03:00 01:46:37
I Total IAdjuvant F~~lu w/ MF1l w/o MF51 Menveo Lyo Other
Viall 12:49:57 114:51:45 _ _11:08:15 112:42:38
Changeover time (End of Production to the end of cleaning+start of set-up to start of production)
Total IAdjuvant Flu w/ MFlu w/o MF Menveo Lyo Other
Vial 05:15:13 05:47:30 05:39:15 04:54:44
Cycle ti me (Start of set-up to the end of clearing)
Total Adjuvant Flu w/ MF lu w/o MF51 Menveo I Lyo Other
Vial 17:48:21 20:39:15 4:30 13:54:05
Ote
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Lyo Other
Lyo Other
M&MA~1 pJ~J 'WI 7 6
9.5 Short Term Cause and Effect Matrix
Author: Zach Wolf
Date: 18-01-12
Novartis Project Selection
Cause and Effect Matrix
Revision: u
9 6 4 7 7 4 9
1 2 3 4 5 6 7
Project Name Function P g .
F F EF UT(D 0
U 0-
oU 0 A) (D)
_ _ _ _ _ _ _ _ _ _ _ _ -]TottaI l
1
2
3
4
5
6
7
8
9
11
12
13
Realign Organization (+formalized feedback)
Fill volume targets
Embed use of VSM to drive improvement
Clear DR backlog + increase CAPA effectiveness
ID underlying causes of issues
Diagnose poor scheduling adherence
Environmental Monitoring excursion reduction
Increase status visibility
Andon and problem response procedures
Clear BPR backlog and reduce BPR review time
Implement Preventative Maintenance/TMP
Continue with DR Reduction Project
Organizational 3 9 9 13 1 9 19 264
Process 9 3 3 9 9_ 3 1 258
Organizational 1 3 9 9 1 9 9 250
Organizational 1 3 9 9 1 9 9 250
Organizational 1 1 9 9 1 9 9 238
Scheduling 1 1 9 9 1 9 9 238
Process 9 3 3 3 3 9 3 216
Organizational 3 1 9 3 3 3 9 204
Organizational 3 1 9 3 3 3 9 204
Organizational 3 1 9 _3 1 3 9 190
Process 3 3 9 3 1 9 3 172
Process 3 3 3 3 9 1 3 172
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9.6 Long Term Cause and Effect Matrix
Author: Zach Wolf
Date: 18-01-12
R i i
Novartis Project Selection
Cause and Effect Matrix
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vs :
7 2 6 7 7 3 9
1 2 3 4 5 6 7
Project Name Function E _ _
>CL
<~ Eu LL -
0 Co o 0)
u Total .2
1 Scheduling algorithm Scheduling 9 1 3 3 9 3 9 257
2 Buffer sizing techniques Scheduling 9 1 3 3 9 3 9 257
3 Robust training and onboarding procedures Organizational 3 3 9 9 3 3 9 255
4 Simplify Work Instructions Process 1 3 9 9 3 3 9 241
5 QA on initial BPR review + simplify/color code Organizational 3 _3 3 _9 9 _3 3 207
6 Decysion/\isual management tool Process 3 1 9 3 3 1 9 203
8 Centralized data database Process 3 3 9 1 3 1 9 193
1_ 1_ t-2- 0
